Babiker H, Borazenci E, Subbiah V, Agarwala S, et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res 2022;28:5079-5087.
PMID: 35917516